150 related articles for article (PubMed ID: 17826092)
41. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
[TBL] [Abstract][Full Text] [Related]
42. 7-imidazolylalkanamido-1-carboxylalkylbenzo-diazepine, a novel series of farnesyltransferase inhibitors.
Wan SB; Chu FM; Guo ZR
Yao Xue Xue Bao; 2002 Jul; 37(7):516-21. PubMed ID: 12914320
[TBL] [Abstract][Full Text] [Related]
43. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
[TBL] [Abstract][Full Text] [Related]
44. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and structure-activity relationships of 4-fluorophenyl-imidazole p38α MAPK, CK1δ and JAK2 kinase inhibitors.
Seerden JP; Leusink-Ionescu G; Woudenberg-Vrenken T; Dros B; Molema G; Kamps JA; Kellogg RM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3412-8. PubMed ID: 24930833
[TBL] [Abstract][Full Text] [Related]
46. Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.
Li YL; Shi E; Burns D; Li Y; Covington MB; Pan M; Scherle P; Friedman S; Metcalf B; Yao W
Bioorg Med Chem Lett; 2009 Sep; 19(17):5037-42. PubMed ID: 19635666
[TBL] [Abstract][Full Text] [Related]
47. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
[TBL] [Abstract][Full Text] [Related]
48. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
49. Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors.
Li B; Cociorva OM; Nomanbhoy T; Weissig H; Li Q; Nakamura K; Liyanage M; Zhang MC; Shih AY; Aban A; Hu Y; Cajica J; Pham L; Kozarich JW; Shreder KR
Bioorg Med Chem Lett; 2013 Sep; 23(18):5217-22. PubMed ID: 23916259
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Patel CH; Dhanani S; Owen CP; Ahmed S
Bioorg Med Chem Lett; 2006 Sep; 16(18):4752-6. PubMed ID: 16870430
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
[TBL] [Abstract][Full Text] [Related]
52. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
Nourry A; Zambon A; Davies L; Niculescu-Duvaz I; Dijkstra HP; Ménard D; Gaulon C; Niculescu-Duvaz D; Suijkerbuijk BM; Friedlos F; Manne HA; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Mar; 53(5):1964-78. PubMed ID: 20148563
[TBL] [Abstract][Full Text] [Related]
53. Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles.
Wiglenda T; Gust R
J Med Chem; 2007 Apr; 50(7):1475-84. PubMed ID: 17352461
[TBL] [Abstract][Full Text] [Related]
54. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
[TBL] [Abstract][Full Text] [Related]
55. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
[TBL] [Abstract][Full Text] [Related]
56. Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.
Boga SB; Alhassan AB; Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Yu Y; Anand R; Liu S; Yang C; Wu H; Cai J; Zhu H; Desai J; Maloney K; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Knemeyer I; Garlisi CG; Bays N; Stivers P; Brandish PE; Hicks A; Cooper A; Kim RM; Kozlowski JA
Bioorg Med Chem Lett; 2017 Aug; 27(16):3939-3943. PubMed ID: 28720503
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
[TBL] [Abstract][Full Text] [Related]
58. Assessing the target differentiation potential of imidazole-based protein kinase inhibitors.
Dimova D; Iyer P; Vogt M; Totzke F; Kubbutat MH; Schächtele C; Laufer S; Bajorath J
J Med Chem; 2012 Dec; 55(24):11067-71. PubMed ID: 23210446
[TBL] [Abstract][Full Text] [Related]
59. 1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
La Regina G; D'Auria FD; Tafi A; Piscitelli F; Olla S; Caporuscio F; Nencioni L; Cirilli R; La Torre F; De Melo NR; Kelly SL; Lamb DC; Artico M; Botta M; Palamara AT; Silvestri R
J Med Chem; 2008 Jul; 51(13):3841-55. PubMed ID: 18529046
[TBL] [Abstract][Full Text] [Related]
60. Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
Lovering F; Kirincich S; Wang W; Combs K; Resnick L; Sabalski JE; Butera J; Liu J; Parris K; Telliez JB
Bioorg Med Chem; 2009 May; 17(9):3342-51. PubMed ID: 19364658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
